High-risk and standard risk/low-risk ALL subjects showed significantly higher expression of 73.61% (p < 0.05) and 69.71% (p < 0.05) positive cells for LLT1 on CD14+ monocytes at diagnosis (1BD) as compared to healthy (44.9%) subjects (Figure 4E). This evidence concerns the gene CLEC2D and acute lymphoblastic leukemia.